Prodcuts
Optimized Molecular Entities™ (OMEs™)


Optimized molecular entities are target-relevant small molecules whose drug-like properties have been optimized for preclinical screening. These OMEs have been derived from cores from our BDC collections. We apply our in-depth knowledge to design and synthesize these molecules. We believe that OMEs have a greater likelihood of success to become development candidates. Currently, we have a 100-membered library that is available for immediate pilot screening. CreaGen continues to produce new libraries and make them available for partners screening.

Capabilities

• Rapid design and synthesis of OME libraries for Lead Discovery and Optimization
• Cycle times of 3-4 weeks from design to delivery
• All compounds purified by reverse phase HPLC
• All compounds quantified and characterized by LCMS (UV214, UV254) and NMR spectroscopy

Capacity

• 10,000 OME library compounds annually
• Typical quantities of 5-10 mg
• Supplied in DMSO solution (96-well plates) or in powder form


Please contact our R & D Coordinator for more information.
 
News
  CreaGen Inc. makes into the 2018 list of major players in CRO industry
https://www.businesswire.com/news/home/20180412005808/en/Outsourcing-Drug-Discovery-Contract-Research-Organization-CRO https://themobileherald.com/contract-research-organization-market-industry-growth-and-forecast-analysis-report-till-2024/24870/ https://www.businesswire.com/news/home/20180412005808/en/Outsourcing-Drug-Discovery-Contract-Research-Organization-CRO   more...
    7th Advances In Chemical Sciences Symposium: May 4th, 2018
The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception   more...
 
 
Home  |  About Us  |  Services  |  Products  |  R&D  |  News  |  Careers  |  Contact us Copyright © 2013 CreaGen Biosciences Inc. All rights reserved.